Abstract
This review will trace the steps in the development of pixantrone dimaleate (initial code BBR 2778, Pixruvi®), an anthracenedione chemotype, as a chemotherapeutic agent. This drug exhibits reduced cardiotoxicity in comparison to anthracyclines and mitoxantrone. Synthetic pathways, biological evaluations and mechanistic considerations will be discussed. On May 10, 2012, the European Medicines Agency granted a conditional marketing approval to CTI Biopharma for pixantrone dimaleate for the treatment of adults suffering from multiple relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). Potential applications of pixantrone dimaleate for the treatment of multiple sclerosis and other maladies will be presented.
Keywords: BBR-2778, cardiotoxicity, non-Hodgkin, lymphoma, pixantrone, Pixuvri®.
Graphical Abstract
Related Books
2-Deoxy-D-Glucose: Chemistry and Biology
Chiral Ionic Liquids: Applications in Chemistry and Technology
Basics of Organic Chemistry: A Textbook for Undergraduate Students
Advances in Organic Synthesis
The Synthetic Methods, Structures, and Properties of the Ca-C σ Bond Organocalcium Containing Compounds
Advances in Organic Synthesis
Chemistry of Bipyrazoles: Synthesis and Applications
Advances in Organic Synthesis
Advanced Nanocatalysis for Organic Synthesis and Electroanalysis
Advances in Organic Synthesis
17